Global X China Biotech Innovation ETF CHB
6.64 USD 0.00 (+0.00%)
At closeFeb 16, 2024, 4:00 PM EST
6.64 Day range 6.70
6.63 52-week range 9.76
News
gurufocus.com Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB) [url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) partner GSK today announced that the U.S. Food and Drug Administration (FDA) has approved Hibsago(bepiro
businesswire.com Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB) CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced that the U.S. Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the…
businesswire.com Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB) PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B…
gurufocus.com Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B [url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) partner GSK today announced positive pivotal data for bepirovirsen, an investigational antisense oligon
accessnewswire.com Challenger Assays Extend New Open Pittable Mineralisation Targeting New JORC Mineral Resources at 'Challenger 3' Target HIGHLIGHTS 8,065m reverse circulation (RC) Resource upgrade drilling recently completed at Challenger ‘Main', ‘Challenger West' (CW) open…
globenewswire.com Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with…
accessnewswire.com Challenger West Assays Return Grades up to 60g/t Au Shallow, high-grade mineralisation in floor of existing open pit HIGHLIGHTS 8,065m reverse circulation (RC) Resource upgrade drilling recently completed at Challenger ‘Main', ‘Challenger West' (CW)…
accessnewswire.com First Challenger Assays Return Grades up to 170g/t Au New zones of high-grade mineralisation identified in open pit walls HIGHLIGHTS 8,065m reverse circulation (RC) Resource upgrade drilling recently completed at Challenger 'Main', 'Challenger West'…
globenewswire.com Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre or Gyre Therapeutics) (Nasdaq: GYRE), a San Diego-based innovative commercial stage biopharmaceutical company with…
globenewswire.com Gyre Therapeutics' Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China Achieved statistically significant ≥1-stage fibrosis regression at Week 52 vs. placebo (52.85% vs.
globenewswire.com Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company with clinical development programs focusing on organ…
proactiveinvestors.co.uk Coca-Cola HBC fizzes to new all-time high Drinks bottler Coca-Cola HBC (ASX:CHB) saw its shares top the FTSE 100 and reach a new all-time high on Thursday morning even though it slowing in profit growth for the coming year. For the past…
globenewswire.com Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on…